News

Euclid Vision Welcomes Specialty Eyecare Professional to Commercial Team

Euclid Vision Corp., a global leader in specialty contact lenses and proactive myopia management initiatives, is pleased to announce the continued expansion of its U.S. sales team with the addition of Jon R. Hudson, ABOC, NCLEC, who has joined the company as account executive for Texas, and Central and Southern U.S. territories. Jon brings 24 years of experience in the eye care industry to his new role.

“We are all very excited to have Jon join our commercial team. The addition of Jon to the U.S. sales force will enable Euclid and Visionary Optics to assist more eye care professionals (ECPs) in providing best-in-class services to more patients, and reinforces our commitment to ECPs and their patients,” said David Bland, Euclid Vision, vice president of sales.

Jon started his career in the eye care industry as a lab technician and optician in both retail and independent eye care practices and followed that by managing independent eye care practices prior to branching off on his own as a practice management consultant. His time with independent practices was focused primarily on maximizing per patient revenue, including the implementation of myopia management programs and initiatives designed to add scleral lenses as a treatment option. Myopia is the leading cause of visual impairment in children worldwide, and its incidence and prevalence are on the rise, with estimates suggesting that more than half of the world’s population will be myopic by 2050. Jon’s passion for myopia management led to his employment with CooperVision Specialty EyeCare, where he held various roles over the course of six years. His primary focus involved development of practice management initiatives for myopia management and training the sales team on implementation of those programs.

Euclid Vision acquired Visionary Optics, a specialty scleral contact lens design and manufacturing pioneer, in 2022. The union of these two companies increases each establishment’s ability to provide comprehensive specialty contact lens care to more patients globally.  “As Euclid Vision and Visionary Optics focus on assisting more ECPs with their efforts to deliver best-in-class specialty contact lens services, in areas such as orthokeratology, scleral, and keratoconus management, Jon’s expansive experience in all sectors of eye care is the perfect fit for our commercial team and the customers we serve in this geographic region,” said Bland.

 

Learn more here.

Recent News

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and

06/02/2026

Contraline Announces $92.5 Million Series B Financing to Advance NES/T Male Contraceptive into Late-Stage Development

Contraline, Inc., a clinical-stage biopharmaceutical company developing novel male contraceptives, today announced the closing of a $92.5 million Series B financing co-led by BVF Partners L.P. and RA Capital Management, with participation from GV (Google Ventures), Lumira Ventures, Invus, and other new and existing investors. In conjunction with the closing of the Series B financing,

06/02/2026

GEN Names BioHealth Capital Region a Top 3 U.S. Biopharma Cluster for Fourth Year in a Row

The BioHealth Capital Region, spanning Maryland, Virginia, and Washington, D.C., has once again been named one of the nation’s Top 3 biopharma clusters by Genetic Engineering & Biotechnology News (GEN), marking the region’s fourth consecutive year in the Top 3. GEN’s 2026 “Top 10 U.S. Biopharma Clusters” ranking was authored by Alex Philippidis, Senior Business